Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on May 13, 2021. The registrant is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on The Nasdaq Stock Market under the symbol NRBO. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Mr. Jeong Gyun Oh notified the Board of his intention to retire upon the expiration of his current term.
- He will not stand for re-election at the 2021 annual meeting of stockholders.
- He intends to continue serving on the Board until immediately prior to the annual meeting.
- The departure is not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the voluntary retirement of a board member.
Investor Verification Checklist
- Verify the correct registrant name is NeuroBo Pharmaceuticals, Inc., not Metavia Inc.
- Confirm the status of the Board of Directors following Mr. Oh's retirement.
- Check for the appointment of a successor director to fill the vacancy.
- Review the upcoming 2021 annual meeting proxy statement for details on the election process.